Doxorubicin (Adriamycin)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Anthracycline; binds and intercalates into DNA, inhibiting nucleotide replication and DNA/RNA polymerase activity. Intercalation of DNA triggers DNA cleavage via topoisomerase II. Toxic effects on organs may be related to cell membrane lipid binding activities; enzymatic electron reduction of doxorubicin creates reactive species, e.g. hydroxyl free radicals OH-, which has been implicated in cardiotoxicity by means of Cu (II) and Fe (III) reduction.[1][2]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Code name: FI-106
  • Generic names: ADM, hydroxydaunorubicin
  • Brand names:
Synonyms
Adriablastina Adriacept Adriacin Adriamycin Adriamycine Adriblastin Adriblastina Adriblastine
Adricept Adricin Adrim Adrimedac Adrosal Antraciclin Biorrub Biorubina
Cadria Carcinocin Cloridrato DE Doxorrubicina Colhidrol Daxotel Deldoxin Dicladox Dobicin
Dobixin Doxo Doxobin Doxo Cell Doxocris Doxokebir Doxolem Doxonolver
Doxor Doxorrubicina Doxoruben Doxorubicina Doxorubicine Doxorubicinum Doxorubin Doxotec
Doxtie Duxocin Evacet Farmiblastina Fauldoxo Flavicina Ifadox Kemodoxa
Lipodox Lyphidox Nagun Neoxane Nuaze Oncodria Onkodox Onkostatil
Pallagicin Ranxas Rastocin Ribodoxo Roxorin Rubex Varidoxo Zodox

References